Sign In
Buy NVO
$47.42
+1.52 (+3.31%)
At Close: Jun 23, 2026
Novo Nordisk nominates Jan van de Winkel and Ramona Sequeira to board
07:14am, Friday, 20'th Feb 2026
Novo Nordisk said on Friday it would nominate Jan van de Winkel and Ramona Sequeira to its board of directors, the first additions since a shake-up at the Danish obesity drugmaker last year.
Healthy Returns: FDA chief Marty Makary on compounded GLP-1s, vaccines and China
02:52pm, Thursday, 19'th Feb 2026
Makary helms the FDA in the midst of a contentious stretch for the agency, defined by massive staff and budget cuts and sweeping changes to vaccine policy.
Stock Market Today: Stocks Slip as U.S.-Iran Tensions Drive Oil Prices to 6-Month High
01:31pm, Thursday, 19'th Feb 2026
Stocks fell on Thursday as oil prices rose to a six-month high amid escalating tensions between the U.S. and Iran.
Novo Nordisk Is Under Pressure - And Trading At A Discount
09:02am, Thursday, 19'th Feb 2026
Novo Nordisk is facing its toughest period in years, yet it remains a 'Strong Buy' and a compelling long-term investment. Novo Nordisk's recent results and 2026 outlook disappointed, with sales and pr
Hims & Hers Q4 Earnings Preview: What To Expect From Upcoming Report
07:04am, Thursday, 19'th Feb 2026
Hims and Hers (HIMS) is set to report fourth-quarter fiscal 2025 results after market close on Feb. 23. Analysts expect earnings to decline, while revenue may see
EU Approves Novo Nordisk's Higher-Dose Wegovy for Obesity Patients
10:45am, Wednesday, 18'th Feb 2026
NVO wins EU nod for a higher 7.2 mg Wegovy dose, unlocking stronger weight-loss results and a new step-up option for obesity care.
Novo Resources Releases Updated Corporate Presentation
06:57pm, Tuesday, 17'th Feb 2026
PERTH, Australia, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Novo Resources Corp. (Novo or the Company) (ASX: NVO) (TSX: NVO) (OTCQB: NSRPF) is pleased to announce the release of its updated corporate present
Novo Nordisk: The Possible Upside
12:36pm, Tuesday, 17'th Feb 2026
Weight loss treatments provider Novo Nordisk might have experienced a sharp stock decline after disappointing 2025 results and 2026 outlook, but it has seen an impressive bounce back since. While the
Novo Nordisk's Wegovy Weight Loss Shot Approved at Higher Dose in EU
09:39am, Tuesday, 17'th Feb 2026
Patients on the higher dose of 7.2 milligrams for about 18 months lost 21% of their body weight on average, a study found.
EU approves higher dose of Novo's Wegovy
09:09am, Tuesday, 17'th Feb 2026
The European Commission has approved a higher dose of Novo Nordisk's popular weight-loss drug Wegovy, the Danish drugmaker said on Tuesday.
Eli Lilly Stock Rises as $1.5 Billion Weight-Loss Pill Prepares to Hit Market
08:59am, Tuesday, 17'th Feb 2026
Eli Lilly (LLY) climbed about 0.5% in premarket trading Tuesday as the company builds roughly $1.5 billion in inventory for its upcoming oral weight-loss pill,
The European Commission has granted final approval of a higher 7.2 mg maintenance dose of Wegovy® (semaglutide) for adults who may need extra help losing weight. It is now approved in all 27 countrie
Novo Nordisk's New Diabetes Drug Outshines Ozempic: Is The Stock a Buy?
03:45pm, Monday, 16'th Feb 2026
Novo Nordisk's next diabetes/weight loss medicine should be better than its current crown jewel. The Danish drugmaker is still facing some challenges, but its pipeline could get it out of trouble.
NVO Crashes 21% in a Month: Is This an Indication to Sell the Stock?
11:30am, Monday, 16'th Feb 2026
Novo Nordisk stock sinks 21% in a month as weak 2026 guidance, slowing semaglutide sales, and rising competition overshadow relatively strong Q4 results.
Novo Nordisk A/S - share repurchase programme
07:21am, Monday, 16'th Feb 2026
Bagsværd, Denmark, 16 February 2026 – On 4 February 2026, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and C
